Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (LEVOCETIRIZINE 5 MG) [ESTUDIO DE LA EFICACIA Y SEGURIDAD DEL ANTIHISTAMINICO V0114CP 2,5 MG EN EL TRATAMIENTO DE LA RINITIS ALERGICA ESTACIONAL. ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE TRES RAMAS Y GRUPOS PARALELOS, QUE INCLUYE UNA RAMA DE PLACEBO Y OTRA DE CONTROL ACTIVO (LEVOCETIRIZINA 5 MG)].

Next Previous
Trial Profile

EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (LEVOCETIRIZINE 5 MG) [ESTUDIO DE LA EFICACIA Y SEGURIDAD DEL ANTIHISTAMINICO V0114CP 2,5 MG EN EL TRATAMIENTO DE LA RINITIS ALERGICA ESTACIONAL. ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE TRES RAMAS Y GRUPOS PARALELOS, QUE INCLUYE UNA RAMA DE PLACEBO Y OTRA DE CONTROL ACTIVO (LEVOCETIRIZINA 5 MG)].

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levomequitazine (Primary) ; Levocetirizine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre

Most Recent Events

  • 31 Jul 2021 Status changed from recruiting to discontinued.
  • 27 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top